Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.15.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.18.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lepu Biopharma Co's EBIT per Share or its related term are showing as below:
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Lepu Biopharma Co was 30.20% per year. The lowest was -15.90% per year. And the median was 7.60% per year.
HKSE:02157's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.3 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Lepu Biopharma Co (HKSE:02157) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lepu Biopharma Co EBIT per Share Related Terms
Lepu Biopharma Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co (HKSE:02157) has a EBIT per Share of HK$0.18 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lepu Biopharma Co and its competitors. According to the industry distribution chart, Lepu Biopharma Co ranks #999999 out of 1171 companies in the Biotechnology industry.
Is Lepu Biopharma Co's EBIT per Share too high?
Lepu Biopharma Co's current EBIT per Share is HK$0.18. Based on the distribution chart, Lepu Biopharma Co ranks #999999 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lepu Biopharma Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #999999 out of 1171 companies for EBIT per Share. This places Lepu Biopharma Co in the lower half of its industry. The industry median EBIT per Share is 15.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.30, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lepu Biopharma Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Biopharma Co's current EBIT per Share is HK$0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.73, compared to a current price of HK$3.83 — trading 77.1% below its estimated fair value. The current EBIT per Share is HK$0.18. Lepu Biopharma Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current EBIT per Share is HK$0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$3.83 is trading 77.1% below its estimated GF Value™ of HK$16.73.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
EBIT per Share: HK$0.18
GF Value™: HK$16.73 vs. price of HK$3.83 (77.1% below fair value)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
45GF Score
Get the complete analysis for HKSE:02157
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
